ProQR to Present at the Leerink Partners 4th Annual Rare Disease Roundtable
LEIDEN, the Netherlands, Sept. 23, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis, today announced that Daniel de Boer, Chief Executive Officer, will take part in an analyst-led fireside chat at the Leerink Partners 4th Annual Rare Disease Roundtable on Wednesday, September 30, 2015 at 1:20pm ET. The conference is being held at Le Parker Meridien in New York, NY, USA.
The live and archived webcast of the fireside chat will be accessible from the 'Investor Relations' section of ProQR's website (www.proqr.com) under 'Events and Presentations'. The archived webcast will be available for 30 days following the presentation date.
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Since 2012.
ProQR Therapeutics N.V.:
Chief Financial Officer
T: +1 415 231 6431
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494